Fracture Prevention Clinical Studies
Our clinical studies group participates in multicentre international
clinical trials evaluating potential osteoporosis treatments that are
in the final stages of pharmaceutical development. We recruit patients
and volunteers who have had a fracture or who have a family history of
osteoporosis. Volunteer participants who meet specific risk criteria
are randomly allocated to receive a new drug or various combinations of
drugs.
Staff
Dr Vivienne Milch |
Dr Yvonne Selecki |
| Clinical Research Associate Jill Hall |
Clinical Research Associate Maureen Gaynor |
News
Study shows that prostate cancer increases the risk of bone fracture
MEDIA RELEASE:
14 May 2008
As unlikely as it sounds, scientists at Garvan have shown that there is a link between prostate cancer and a higher risk of bone fracture. Their study suggests that men with prostate cancer face a 50% higher risk of fracture, which increases to nearly 100% if they are receiving androgen deprivation therapy for their prostate cancer.
Genotyping takes us closer to an osteoporosis fingerprint
MEDIA RELEASE:
30 Apr 2008
Garvan collaborated with the Icelandic genetics company, deCode, in an extensive multi-nation genome-wide search to find the genes linked to osteoporosis and fracture. Five regions of interest have been identified that appear to warrant further scientific investigation.
Osteoporosis: Men told to watch their step
25 Jan 2007
Garvan scientists say that men need to realise osteoporosis is not just a disease of elderly women and that once men over the age of 60 have had a fracture, around one in three will have broken another bone within just a few years.
